Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EPS (Basic): 2014-2024

Historic EPS (Basic) for Summit Therapeutics (SMMT) over the last 11 years, with Dec 2024 value amounting to -$0.31.

  • Summit Therapeutics' EPS (Basic) fell 287.50% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.25, marking a year-over-year decrease of 420.83%. This contributed to the annual value of -$0.31 for FY2024, which is 68.69% up from last year.
  • Latest data reveals that Summit Therapeutics reported EPS (Basic) of -$0.31 as of FY2024, which was up 68.69% from -$0.99 recorded in FY2023.
  • In the past 5 years, Summit Therapeutics' EPS (Basic) ranged from a high of -$0.31 in FY2024 and a low of -$0.99 during FY2023.
  • Over the past 3 years, Summit Therapeutics' median EPS (Basic) value was -$0.41 (recorded in 2022), while the average stood at -$0.57.
  • In the last 5 years, Summit Therapeutics' EPS (Basic) tumbled by 141.46% in 2023 and then spiked by 68.69% in 2024.
  • Over the past 5 years, Summit Therapeutics' EPS (Basic) (Yearly) stood at -$0.76 in 2020, then grew by 11.84% to -$0.67 in 2021, then skyrocketed by 38.81% to -$0.41 in 2022, then plummeted by 141.46% to -$0.99 in 2023, then surged by 68.69% to -$0.31 in 2024.